SJP 002

Drug Profile

SJP 002

Alternative Names: SJP002

Latest Information Update: 14 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Samjin Pharmaceutical Company
  • Class Anti-inflammatories; Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Dry eyes

Most Recent Events

  • 01 Sep 2016 Phase-I clinical trials in Dry eyes (In volunteers) in South Korea (Ophthalmic) (NCT02924155)
  • 11 Jul 2016 Preclinical trials in Dry eyes in South Korea (Ophthalmic) before July 2016
  • 11 Jul 2016 Samjin Pharmaceutical receives clinical approval from Korean FDA for SJP 002 in Dry eyes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top